title: Protective effects of polydeoxyribonucleotides on cartilage degradation in experimental cultures.
abstract: The capacity of cartilage self-regeneration is considered to be limited. Joint injuries often evolve in the development of chronic wounds on the cartilage surface. Such lesions are associated with articular cartilage degeneration and osteoarthritis. Re-establishing a correct micro/macro-environment into damaged joints could stop or prevent the degenerative processes. This study investigated the effect of polydeoxyribonucleotides (PDRNs) on cartilage degradation in vitro and on cartilage extracted cells. The activities of matrix metalloproteinases 2 and 9 were measured in PDRN-treated cells and in controls at days 0 and 30 of culture. Human nasal cartilage explants were cultured, and the degree of proteoglycan degradation was assessed by measuring the amount of glycosaminoglycans released into the culture medium. The PDRN properties compared with controls were tested on cartilage tissues to evaluate deposition of extracellular matrix. Chondrocytes treated with PDRNs showed a physiological deposition of extracellular matrix (aggrecan and type II collagen: Western blot, IFA, fluorescence activated cell sorting, Alcian blue and safranin O staining). PDRNs were able to inhibit proteoglycan degradation in cartilage explants. The activities of matrix metalloproteinases 2 and 9 were reduced in all PDRN-treated samples. Our results indicate that PDRNs are suitable for a long-term cultivation of in vitro cartilage and have therapeutic effects on chondrocytes by protecting cartilage.
authors.affiliation: Consorzio Carso Laboratories, 70010 Valenzano, Bari, Italy. luisagennero@yahoo.com
authors.forename: Luisa
authors.initials: L
authors.lastname: Gennero
authors.forename: Tetyana
authors.initials: T
authors.lastname: Denysenko
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Calisti
authors.forename: Andrea
authors.initials: A
authors.lastname: Vercelli
authors.forename: Carlo Maria
authors.initials: CM
authors.lastname: Vercelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Amedeo
authors.forename: Silvia
authors.initials: S
authors.lastname: Mioletti
authors.forename: Enrico
authors.initials: E
authors.lastname: Parino
authors.forename: Manuela
authors.initials: M
authors.lastname: Montanaro
authors.forename: Antonio
authors.initials: A
authors.lastname: Melcarne
authors.forename: Carola
authors.initials: C
authors.lastname: Juenemann
authors.forename: Enrico
authors.initials: E
authors.lastname: De Vivo
authors.forename: Alessandro
authors.initials: A
authors.lastname: Longo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cavallo
authors.forename: Rocco
authors.initials: R
authors.lastname: De Siena
mesh_terms: D000328:Adult; D053674:Aggrecans / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D019902:Chondrocytes / Q000166:cytology / Q000378:metabolism; D024043:Collagen Type II / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D055171:Nasal Cartilages / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011089:Polydeoxyribonucleotides / Q000494:pharmacology*; D020011:Protective Agents / Q000494:pharmacology*
chemical_list: D053674:Aggrecans; D024043:Collagen Type II; D011089:Polydeoxyribonucleotides; D020011:Protective Agents; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9